ocrelizumab news

All news on ocrelizumab (also known as Ocrevus): plants, production capacities, investments and involved companies.

18 September 2026

Roche: CHMP recommends Ocrevus for paediatric relapsing MS (age 10+)

CHMP backs ocrelizumab for relapsing MS in patients aged 10 and older after Phase III showed stronger lesion suppression and comparable relapse control versus fingolimod.

Who will be producing ocrelizumab in the future?

Find out with chemXplore Alpha

Learn more